Eli Lilly stock slips as new orforglipron data raises side-effect questions vs Novo pill
Eli Lilly shares fell about 1% Thursday after new trial data showed its experimental weight-loss pill, orforglipron, caused more stomach-related side effects and patient dropouts than Novo Nordisk’s rival drug. The ACHIEVE-3 trial found Lilly’s pill led to greater blood sugar and weight reduction, but 10% discontinued due to side effects, double the rate seen with Novo’s oral semaglutide.